Scholar Rock Holding SRRK
United StatesHealthcare · BiotechnologyUSD
70.44 USD (+66.9%)
16 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases with high unmet medical need, focusing on selective inhibition of TGF-beta family proteins.
Key points
from its scores- ✓Good share-price trend7.7
- ✓Favourable backdrop7.4
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.8
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHighly speculative investment: only suitable for very high-risk profiles betting on the success of its clinical programs; the current price already discounts an optimistic scenario.
Scholar Rock is a clinical-stage biotech with no revenue, a solid cash position (liquidity 7.02) and low debt, but with an ROE of -167.77% reflecting cash burn. Its valuation (FCF yield -2.99) is speculative and depends on the success of its clinical trials, making it a high-risk, high-potential-reward investment.
The main risk is regulatory and business model: the failure of a key clinical trial or the non-approval of a drug by the FDA could destroy most of the company's value.
Context and risks
Clinical-stage biotech company with no revenue and an ROE of -167.77%, reflecting typical cash burn in the sector. The main risk is regulatory and business model: it depends on the success of its clinical trials and FDA approval for its drug candidates, a process with high uncertainty and no guarantee of success.
Is Scholar Rock Holding stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 20.2 | 4.1 | +392% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 70.44 USD, +66.9% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −16.6
- EV / EBITDA
- −12.0
- Price / book
- 20.2
- Market cap
- 5.1B USD
- Enterprise value
- 4.9B USD
Profitability
- ROE
- −167.8%
- ROA
- −58.8%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −153.9M USD
- FCF yield
- −3.0%
Solvency
- Total debt
- 203.8M USD
- Net debt
- −288.3M USD
- Cash
- 492.1M USD
- EBITDA
- −404.9M USD
- Net debt / EBITDA
- 0.71
- Debt / equity
- 80.32
- Current ratio
- 7.02
- Quick ratio
- 6.84
Growth
- EPS (TTM)
- −3.32 USD
- EPS (forward)
- −2.55 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.62
- Analyst consensus
- Strong buy (16)
- Target price
- 70.44 USD
- 52-week range
- 27.07 – 61.76
Recent news
All SRRK news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Scholar Rock Holding
Is Scholar Rock Holding stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 70.44 USD, +66.9% versus the price. This is not investment advice.
What score does Scholar Rock Holding get on MeridIAn Screener?
It scores 3.2 out of 10, rank 2,069 of 2,130 (better than 3% of the companies analysed). Its strongest category is Momentum (7.7) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Scholar Rock Holding worth on the stock market?
Its market capitalisation is 5.1B USD and its enterprise value, debt included, is 4.9B USD.
How much debt does Scholar Rock Holding have?
It has more cash than debt: net cash of 288.3M USD.
Does Scholar Rock Holding pay a dividend?
It pays no dividend, or almost none.
How has Scholar Rock Holding stock performed over the last year?
It has risen 6.9% over the last year, excluding dividends. Over the last 52 weeks it has traded between 27.07 and 61.76 USD. Past performance does not guarantee future results.
What do analysts think of Scholar Rock Holding?
16 analysts cover it; their average recommendation is “Strong buy” and their average target is 70.44 USD (+66.9% versus the price). It is an estimate, not market data.